Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

• Published in: Nature communications 2021-10, Vol.12 (1), p.5866-11, Article 5866
• Main Authors: Cao, Xuezhi, Liang, Yong, Hu, Zhenxiang, Li, Huiyu, Yang, Jiaming, Hsu, Eric J., Zhu, Jiankun, Zhou, Jin, Fu, Yang-Xin
• Format: Article
• Language: English
• Subjects: 38; 38/1; 631/250/580; 631/67/327; 64; 64/60; 692/4028/67/580; 82/1; Animals; Anticancer properties; Antigen presentation; Antineoplastic Agents - immunology; Antitumor agents; CD8 antigen; CD8-Positive T-Lymphocytes - immunology; Cell Line, Tumor; Cryoelectron Microscopy; Half-life; Haplorhini; Humanities and Social Sciences; Immune checkpoint; Immune response; Immune system; Immunity; Immunotherapy; Interferon; Interferon Type I - immunology; Kinetics; Metastases; Mice; multidisciplinary; Pharmacokinetics; Priming; Radiation; Radioactive half-life; Science; Science (multidisciplinary); Side effects; Solid tumors; Toxicity; Tumor Microenvironment; Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-021-26112-2

Type I interferon is promising in treating different kinds of tumors, but has been limited by its toxicity, lack of tumor targeting, and very short half-life. To target tumors, reduce systemic toxicity, and increase half-life, here we engineer a masked type I IFN-Fc (ProIFN) with its natural receptor connected by a cleavable linker that can be targeted by tumor-associated proteases. ProIFN has a prolonged serum half-life and shows an improved tumor-targeting effect. Interestingly, ProIFN-treated mice show enhanced DC cross-priming and significant increased CD8 + infiltration and effector function in the tumor microenvironment. ProIFN is able to improve checkpoint blockade efficacy in established tumors, as well as radiation efficacy for both primary and metastatic tumors. ProIFN exhibits superior long-term pharmacokinetics with minimal toxicity in monkeys. Therefore, this study demonstrates an effective tumor-activating IFN that can increase targeted immunity against primary tumor or metastasis and reduce periphery toxicity to the host. Several studies have demonstrated that IFN-I administration can boost anti-tumor immune response against solid tumors. Here, to overcome the limitations of systemic IFN-I therapy (side effects, short half-life), the authors design a masked IFN-I prodrug activatable by tumor-associated proteases, showing preserved anti-tumor activity but reduced toxicity.